Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment.
Remissions of haematological malignancies have been reported after allo-SCT, despite donor cell rejection, suggesting that sustained allogeneic engraftment is not mandatory to obtain a lasting anti-tumour effect. To evaluate the potential benefit from transient post-allo-SCT alloreactivity, we took advantage of the Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC) registry to colligate 14 patients with an efficient and long-lasting allogeneic (GVL) effect after allo-SCT for haematological malignancies, despite transient or absent engraftment. None received a second allogeneic graft after autologous recovery. The median duration of remission after autologous reconstitution was 118 (12-252) months. Although we cannot exclude the possibility that some patients were cured before allo-SCT, this retrospective analysis does strongly suggest that an efficient GVL effect can be observed without sustained donor engraftment, and that the transient presence of donor T cells might be sufficient to induce a powerful GVL effect.
Service d'Hématologie, Centre Hospitalier Universitaire Jean Minjoz, Besançon France. edeconinck@chu-besancon.fr
E
E
Daguindau
B
B
Lioure
A
A
Buzyn
M
M
Robin
C
C
Faucher
M
M
Kuentz
P
P
Tiberghien
E
E
Deconinck
D000328:Adult; D002675:Child, Preschool; D006085:Graft Survival; D020544:Graft vs Leukemia Effect / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000601:surgery*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive; D008875:Middle Aged; D014019:Tissue Donors; D018183:Transplantation Chimera; D014184:Transplantation, Homologous